Nitrosamine Testing in Supplements and Cosmetics: How FDA's Expanding Guidance Changes Your Risk Picture

In 2018, a routine manufacturing audit at a Chinese API supplier uncovered something the entire valsartan supply chain had never tested for: N-Nitrosodimethylamine (NDMA) at concentrations well above what FDA would later establish as the acceptable daily intake of 96 nanograms per day. That discovery triggered the largest pharmaceutical recall cascade in recent FDA history — valsartan, losartan, irbesartan, then metformin, then ranitidine. Hundreds of millions of units pulled from shelves. Billions in liability exposure.

The pharmaceutical industry spent the next three years building nitrosamine control programs from scratch: risk assessments, validated LC-MS/MS methods, supplier qualification protocols, packaging evaluations. It wasn’t cheap or fast. And while supplement and cosmetic brands largely watched from the sidelines, FDA was already asking where these same compounds might be forming outside of pharma.

That question is no longer theoretical. FDA has issued Warning Letters to dietary supplement companies citing NDMA contamination. Cosmetic formulations containing secondary amines have been under informal agency scrutiny for decades. With USP <1469> now providing a testing and control framework that extends well beyond the pharmaceutical context, brands that haven’t started thinking about nitrosamine risk are genuinely behind — and getting further behind with each new FDA enforcement action.

From Pharmacy Shelves to Supplement Aisles: How This Risk Spread

Nitrosamines aren’t new chemistry. FDA first flagged nitrosamine contamination concerns in cosmetic products back in the 1970s, and the scientific classification of NDMA as a probable human carcinogen (IARC Group 2A) predates most of today’s regulatory frameworks. What changed after 2018 was the scale of documented contamination and, more importantly, FDA’s willingness to treat nitrosamine presence in consumer products as an enforcement priority rather than an academic concern.

The pharmaceutical recalls revealed an uncomfortable truth: the chemistry that generates nitrosamines isn’t confined to API synthesis. NDMA and its relatives form when secondary or tertiary amines react with nitrosating agents — nitrous acid, nitrogen oxides, nitrite impurities — under conditions of elevated temperature, low pH, or high moisture. That reaction pathway exists in supplement raw material processing, in cosmetic formulation, and in finished products sitting in warehouses or shipping containers during summer months.

FDA established acceptable intake (AI) limits for the most common pharmaceutical nitrosamines based on a 1-in-100,000 excess lifetime cancer risk over a 70-year exposure period. NDMA: 96 ng/day. NDEA (N-Nitrosodiethylamine): 26.5 ng/day. Higher-potency impurities like NMBA and NIPEA carry lower limits still. These thresholds weren’t written with protein powders or face serums in mind — but in the absence of supplement- or cosmetic-specific guidance, they’re the closest thing to an actionable benchmark the industry has right now, and they’re the reference point FDA will reach for when it opens an investigation.

Which Ingredients and Product Categories Carry the Highest Risk

Not all supplements and cosmetics carry equal nitrosamine risk. The chemistry tells you where to focus first.

Secondary and tertiary amines are the primary precursors. In dietary supplements, the ingredients worth evaluating include DMAE (dimethylaminoethanol), choline bitartrate, L-carnitine salts, trimethylglycine (betaine), and certain botanical extracts processed with solvent systems that may introduce nitrosating contaminants. Some marine- and yeast-derived protein hydrolysates contain elevated amine concentrations that warrant dedicated screening. Fish oil concentrates — depending on how they’re processed — represent another category that comes up in risk assessments more than brands expect.

In cosmetics, the formation risk is better documented, if not better managed. Formulations that combine secondary alkanolamines — triethanolamine (TEA), diethanolamine (DEA), monoethanolamine (MEA) — with formaldehyde-releasing preservatives such as DMDM hydantoin, imidazolidinyl urea, or diazolidinyl urea create exactly the conditions needed for N-nitrosamine formation. FDA has been aware of this since at least the mid-1990s. But awareness hasn’t driven mandatory testing requirements for cosmetics, which means a meaningful share of products currently on shelves have never been screened.

Packaging is an underappreciated contamination pathway. Certain elastomers — rubber closures, silicone seals, and gaskets used in supplement containers and cosmetic pump dispensers — can leach nitrosamines directly into the product over time. This mechanism was a documented contamination pathway in several pharmaceutical recalls. For supplements in softgel formats or products with elastomeric packaging components, packaging materials belong in the risk assessment, not just the formulation.

Finally, storage conditions matter more than most brands account for. Elevated temperature and humidity accelerate nitrosamine formation in susceptible formulations. A product that passes screening at the time of manufacture may accumulate NDMA over its shelf life if the underlying chemistry is there and the packaging doesn’t adequately control moisture and temperature exposure. Stability-indicating nitrosamine testing — testing samples pulled at multiple time points under real and accelerated storage conditions — is the only way to characterize this risk properly.

How Nitrosamine Testing Actually Works — and Why Method Choice Matters

There’s no single validated standard method for nitrosamine testing in dietary supplements or cosmetics, which creates real variability in what different labs can and do report. The two primary analytical platforms are GC-MS/MS and LC-MS/MS, and they are not interchangeable.

GC-MS/MS with headspace injection is well-suited for volatile nitrosamines — NDMA and NDEA, both small molecules, partition efficiently into the headspace above the sample matrix. It’s a mature methodology with good sensitivity for these specific analytes; detection limits in the low parts-per-billion (ppb) range are achievable with proper method development. For a first-pass risk screen, a GC-MS/MS panel targeting the six nitrosamines that FDA has prioritized in pharmaceutical contexts (NDMA, NDEA, NMBA, NIPEA, NDIPA, NDBA) is a reasonable starting point.

LC-MS/MS is better suited for less volatile nitrosamines, for compound-specific confirmation, and for complex matrices like botanical extracts or protein-rich supplements where headspace GC would miss higher-molecular-weight analytes. USP <1469> references LC-MS/MS as the primary methodology for comprehensive impurity profiling, and most rigorous pharmaceutical nitrosamine work has been done on LC platforms. If a GC screen raises flags, or if your formulation contains amine-rich ingredients that suggest broader risk, LC-MS/MS follow-up is the appropriate next step.

The variable that brands most commonly overlook when reviewing a COA is detection limit. Reporting at 10 ppb and reporting at 0.1 ppb are not equivalent — but both can appear on a certificate of analysis labeled “below detection.” When you’re evaluating against FDA’s 96 ng/day threshold for NDMA, and your product has a 3-gram serving, you’re working with a permissible concentration in the low parts-per-billion range. If your testing lab’s method can’t achieve that sensitivity in your specific matrix, the negative result on your COA doesn’t actually tell you what you think it does.

When we work with clients on nitrosamine testing programs, the first conversation is always about matrix and serving size. Both variables determine the required detection limit. Both determine which analytical method is appropriate. A lab that doesn’t ask those questions upfront is either using a one-size-fits-all approach or hasn’t done this work seriously.

What FDA Currently Expects — and Where the Regulatory Trajectory Points

FDA hasn’t issued supplement-specific nitrosamine guidance with the same formality as its pharmaceutical framework — not yet. The practical significance of that “yet” depends on how closely you’ve been watching FDA’s enforcement pattern over the past five years.

Enforcement actions against supplement companies citing NDMA contamination have proceeded under existing GMP regulations at 21 CFR Part 111, which requires manufacturers to establish identity, purity, strength, and composition for all dietary ingredients. FDA doesn’t need a nitrosamine-specific rule to issue a Warning Letter; it needs evidence that a contaminant is present at a level that raises safety concerns, and NDMA at levels exceeding established pharmaceutical thresholds provides exactly that basis.

USP <1469>, published as an informational general chapter, provides a risk assessment and control strategy framework that any quality-focused supplement or cosmetic brand can use right now. It’s not mandatory for dietary supplements in the way it applies to pharmaceutical compounding — but it’s what a sophisticated buyer, retailer, or Amazon compliance reviewer will increasingly expect to see behind a clean COA. The chapter outlines a systematic approach: identify potential nitrosamine sources in raw materials and manufacturing, evaluate formation conditions, conduct confirmatory testing on high-risk products, and document your rationale.

FDA’s 2021 guidance on nitrosamine impurities in human drugs laid out a risk assessment framework that maps cleanly onto supplement and cosmetic manufacturing. The chemistry is the same. The manufacturing inputs and formation pathways are the same. The only difference is the regulatory citation. It would be a significant surprise if FDA’s approach to supplements and cosmetics diverges dramatically from what it’s built for pharmaceuticals — and the trajectory of Warning Letters and informal guidance suggests it won’t.

What to Do Before You Need To

The brands that benefit most from FDA’s eventual formal guidance are the ones that won’t be surprised by it. Three concrete steps worth taking now:

Start with a written risk assessment. Walk through your formulations and identify any secondary or tertiary amine-containing ingredients. Review your packaging materials for elastomeric components. Document storage and shipping conditions for temperature-sensitive products. This doesn’t require a formal study — it requires someone sitting down with your formulations and thinking systematically about where nitrosamine precursors exist.

Confirm your testing lab’s method sensitivity before ordering testing. Ask specifically: what is the limit of detection for NDMA in my product matrix, and how was that validated? A lab that can’t answer that question clearly shouldn’t be doing your nitrosamine screening.

Build confirmatory testing into your documentation for high-risk products. A COA showing nitrosamine screening results, with the method and detection limits clearly stated, is documentation that demonstrates due diligence. If FDA raises the question — and for supplement and cosmetic categories with amine-containing formulations, that question is increasingly likely — your answer should already be on file.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• Preparing for an FDA Regulatory Audit: What the 21 CFR Framework Actually Requires — Aurora TIC covers FDA compliance strategy, audit readiness, and how CFR Part 111 intersects with emerging contaminant guidance.
• Nitrosamine Risk Assessment for Canadian NHP Products: What Health Canada Expects — Androxa explores how Health Canada’s Natural Health Product regulations apply to NDMA and nitrosamine contamination concerns in the Canadian market.
• Raw Material Qualification for Amine-Containing Supplement Ingredients — Ayah Labs on supplier qualification, COA verification, and screening strategies for ingredients with elevated nitrosamine formation potential.